AzTrials
AzTrials

Chronic Pelvic PainNCT07841171

Clinical Observation on the Efficacy of Acupoint Force Therapy Devices in the Intervention of Chronic Pelvic Pain

A study testing EMMA Robot-assisted Tuina in people with Chronic Pelvic Pain, run by Peking University Third Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The present study is a prospective,single-center, single-arm, pre-post control clinical trial conducted at Peking University Third Hospital. 20 participants will be recruited into CCP group,Clinical outcomes will be evaluated at baseline, one week and two weeks after treatment and two weeks follow-up after treatment… Read more about this study

Who is it for?
Ages 20 to 50 years, women only
Conditions the study is for
Chronic Pelvic Pain
What is being tested?
EMMA Robot-assisted Tuina
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
No sites listed yet
Study dates
30 Sep 2026to 30 Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Meet the diagnostic criteria for chronic pelvic pain;
  • Disease duration greater than 6 months;
  • Female patients aged 20-50 years;
  • Married or unmarried with history of sexual activity;
  • Not concurrently participating in other clinical studies;
  • Voluntarily participate in this trial and provide signed informed consent. Note: Patients must meet all 6 criteria above to be enrolled in this study.

Who cannot join

  • Altered consciousness, inability to cooperate and complete the study, or presence of psychiatric disorders;
  • Concomitant severe diseases of the cardiovascular, cerebrovascular, hepatic, renal, urinary, digestive, or reproductive systems;
  • Concomitant severe spine-related conditions, such as spinal fracture, spinal infection, severe osteoporosis, spondylolisthesis, or spinal instability;
  • Presence of skin lesions, infections, ulcers, or severe dermatological conditions in the treatment area;
  • Pregnant, planning pregnancy, or lactating women;
  • Abdominal, pelvic, lumbar, or pelvic-related surgery or invasive procedures within the past 12 months;
  • Currently participating in other clinical trials. Note: Individuals meeting any one of the above criteria shall be excluded.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Haolin Zhang, Doctor contact

15611963539 ext. Ext.86

zoe@bjmu.edu.cn

About this study

The present study is a prospective,single-center, single-arm, pre-post control clinical trial conducted at Peking University Third Hospital. 20 participants will be recruited into CCP group,Clinical outcomes will be evaluated at baseline, one week and two weeks after treatment and two weeks follow-up after treatment termination.

The primary outcome measure is the Visual Analogue Scale (VAS) pain score before and after treatment. Secondary outcomes include Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), Numerical Rating Scale (NRS), SF-36 Health Survey, Short-form McGill Pain Questionnaire (SF-MPQ), adverse event incidence rate, and analgesic medication use frequency.Adverse events will be assessed at every visit. Both the CRF and web-based electronic database, REDCap (edc.bjmu.edu.cn), will be used to manage individual participant data by two data entry personnel independently. SPSS V.25.0 statistical software was used for analysis. This report describes the study design of the clinical trial.

Read the detailed description

Chronic pelvic pain (CPP) is defined as non-cyclic pain localized in the pelvic region, primarily involving the lower abdomen and lumbosacral area, persisting for more than 6 months. In 2020, the American College of Obstetricians and Gynecologists (ACOG) consensus classified the etiologies of CPP into three major categories: organ diseases, neuromusculoskeletal abnormalities, and psychosocial factors. CPP is a challenging condition estimated to affect 15%-26% of the female population worldwide. Both patients and clinicians often feel frustrated by the limited treatment options available. Furthermore, chronic pelvic pain frequently overlaps with non-pelvic pain conditions (such as fibromyalgia and migraines) as well as non-painful comorbidities (including sleep disorders, mood disorders, and cognitive dysfunction), thereby exacerbating pain severity and leading to functional impairment. A wide array of clinical therapeutic regimens is available, consisting of pharmacotherapy, physical therapy, cognitive-behavioral interventions, and surgery tailored to specific patient populations. Nevertheless, current therapeutic strategies are hampered by inconsistent efficacy and substantial clinical difficulties, stemming from multifactorial etiologies, poor long-term medication adherence coupled with severe adverse effects, as well as the tendency of the condition to persist and recur frequently. Therefore, there is a clinical need for safer, more effective treatment regimens suitable for long-term intervention.

Acupoint massage achieves meridian regulation and analgesic effects through manual stimulation; it is non-invasive, safer, and more acceptable to patients. Nevertheless, traditional manual acupoint massage is similarly constrained by practitioner experience variability, difficulties in standardizing pressure intensity, and substantial time and labor demands on medical staff, making it difficult to achieve stable, quantifiable, and long-term sustainable treatment requirements. Therefore, intelligent technology-based acupoint mechanical stimulation devices capable of precise control over stimulation intensity, frequency, and duration provide a new technological pathway for the sustained and standardized management of chronic pain.

EMMA is a non-invasive acupoint mechanical stimulation device designed for standardized surface intervention. It measures patients' muscle hardness through sensors and 3D vision, identifies pressure points, and provides precise acupoint stimulation to help patients relieve pain and release tension. Our team participated in a study led by Professor Claudia Witt's research group on the effectiveness of app-based acupoint acupressure therapy for women with menstrual pain. In that study, 221 women were divided into an acupoint pressure group and a usual care group, receiving acupressure intervention over 6 menstrual cycles (6 acupoints, 1 minute per acupoint, continuous pressure for 5 days before menstruation). The results showed that the average pain intensity in the third menstrual cycle was significantly lower in the acupressure group compared to the usual care group, with significant differences observed by the sixth cycle. These findings indicate that acupoint pressure can effectively reduce lower abdominal pain during menstruation, providing a theoretical basis for the conduct of this study.

Accordingly, based on preliminary research findings, this project adopts the EMMA acupoint mechanical therapy device for patient treatment, with the objective of evaluating the efficacy and safety of this device in managing chronic pelvic pain. Improvements in patients' symptoms will be assessed via changes in outcome measures including the Visual Analogue Scale (VAS) for pain.

The present study is a prospective,single-center, single-arm, pre-post control clinical trial design with a 2-week study duration. The interventions to be tested are EMMA Massage Therapy(3 times/week for a total of 6 sessions over 2 weeks). Participants will be enrolled at at Peking University Third Hospital, Beijing China.

The design of this study is compliant with the Consolidated Standards of Reporting Trials (CONSORT) guidelines and with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement 2013(Table 1). The study protocol has been approved by the Regional Ethical Review Board of Peking University Third Hospital, China. Approval Number: ID: M20260476.

CCP is characterized by pain and tenderness in the lower abdomen and lumbosacral region. Pathologically, CPP involves chronic inflammation and adhesions of pelvic organs, persistent myofascial tension in the pelvic floor muscles, and a hyperactive state of pain transmission pathways due to central sensitization; these three factors interact synergistically, leading to chronic and diffuse pain. Therefore, treatment requires simultaneous intervention at both peripheral and central levels. From the perspective of Traditional Chinese Medicine Meridian theory, the lower abdomen falls under the jurisdiction of the Ren Meridian, while the lumbosacral region is governed by the Bladder Meridian and Du Meridian-the distribution of CPP pain closely corresponds to the pathways of these meridians. Based on the above, our specific plan is as follows:

①Back acupoint massage (30 minutes) Based on the pathway of the Foot Taiyang Bladder Meridian on the back, the treatment duration is 30 minutes. The massage pressure is set at 30N as the baseline, taking into account the patient's tolerance.

②Abdominal acupoint and tender point massage Based on meridian-disease correlations and expert consensus, we selected Zhongwan (CV12), bilateral Tianshu (ST25), bilateral Guilai (ST29), Guanyuan (CV4), and relevant tender points (Ashi points) for massage in a clockwise sequence. The massage pressure is set at 30 N as the baseline, adjusted according to patient tolerance. And the treatment duration per acupoint is 1 minute as the baseline. Both the pressure and duration may be adjusted according to the patient's individual condition, and additional tender points may be included as appropriate based on the participant's presentation.

Being tested
EMMA Robot-assisted Tuina
Keywords
EMMA, the Visual Analogue Scale (VAS) pain score, Chronic Pelvic Pain, pre-post control clinical

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EMMA Robot-assisted TuinaDevice

    ①Back acupoint massage (30 minutes) Based on the pathway of the Foot Taiyang Bladder Meridian on the back, the treatment duration is 30 minutes. The massage pressure is set at 30N as the baseline, taking into account the patient's tolerance.The specific acupoints are illustrated in the figure below.

    ②Abdominal acupoint and tender point massage Based on meridian-disease correlations and expert consensus, we selected Zhongwan (CV12), bilateral Tianshu (ST25), bilateral Guilai (ST29), Guanyuan (CV4), and relevant tender points (Ashi points) for massage in a clockwise sequence. The massage pressure is set at 30 N as the baseline, adjusted according to patient tolerance. And the treatment duration per acupoint is 1 minute as the baseline. Both the pressure and duration may be adjusted according to the patient's individual condition, and additional tender points may be included as appropriate based on the participant's presentation.

Study groups in NCT07841171
Study groupRoleWhat they receive
All participants will recept EMMA treatment in EMMA treatmentExperimentalThe present study is a prospective,single-center, single-arm, pre-post control clinical trial design with a 2-week study duration. The interventions to be tested are EMMA Massage Therapy.Participants will recive 3 times/week for a total of 6 sessions over 2 weeks.
Receives: Device: EMMA Robot-assisted Tuina

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome is the Visual Analogue Scale (VAS) at week 2 (end of treatment).A scale of 0-10 represents different degrees of pain, with 0 representing "no pain" and 10 representing "unbearable pain."

    The primary outcome is the Visual Analogue Scale (VAS) at week 2 (end of treatment).A scale of 0-10 represents different degrees of pain, with 0 representing "no pain" and 10 representing "unbearable pain." Patients mark the position corresponding to their pain severity on the scale; higher scores indicate more severe pain.

    Measured: We will administer VAS scale assessments at four time point: basline, After 1 week of treatment, 2 weeks of treatment and follow-up 2 weeks after last treatment : All baseline measures are repeated measures.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2026
  2. Study start30 Sep 2026 (estimated)
  3. Primary completion31 Mar 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
The present study is a prospective,single-center, single-arm, pre-post control clinical trial design with a 2-week study duration.
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07841171
Sponsor's protocol ID
Peking UTH
Status last verified
Aug 2026
First submitted
9 Sep 2026
Last updated
25 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Given that the data involves patient privacy and the relevant parameters of the EMMA device, the IPD data of this study will not be shared.

Questions about this trial

What is this clinical trial studying?

A study testing EMMA Robot-assisted Tuina in people with Chronic Pelvic Pain, run by Peking University Third Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Haolin Zhang, Doctor (15611963539 ext. Ext.86, zoe@bjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome is the Visual Analogue Scale (VAS) at week 2 (end of treatment).A scale of 0-10 represents different degrees of pain, with 0 representing "no pain" and 10 representing "unbearable pain." (time frame: We will administer VAS scale assessments at four time point: basline, After 1 week of treatment, 2 weeks of treatment and follow-up 2 weeks after last treatment : All baseline measures are repeated measures.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in